middle.news
Why Are Mesoblast’s Ryoncil Revenues Soaring 69% This Quarter?
9:56am on Monday 20th of October, 2025 AEDT
•
Healthcare
Read Story
Why Are Mesoblast’s Ryoncil Revenues Soaring 69% This Quarter?
9:56am on Monday 20th of October, 2025 AEDT
Key Points
69% increase in Ryoncil net sales to US$19.1 million in Q1 FY2026
Permanent CMS J-Code assigned, enhancing reimbursement and billing
US$145 million cash on hand with reduced operating cash spend
Convertible note agreements up to US$50 million pending shareholder approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE